Core Viewpoint - LifeStance Health Group, Inc. (NASDAQ:LFST) is identified as a promising stock under $20, with a price target increase from $9 to $10 by Canaccord, reflecting strong growth expectations in revenue and adjusted EBITDA for fiscal Q4 and 2026 [1][3] Financial Performance - For fiscal Q4, LifeStance reported revenues of $382.2 million, a 17% increase year-over-year, and for the full year 2025, total revenue reached $1.424 billion, up 14% [3] - The clinician base grew by 9% to 8,040 clinicians, with a net increase of 44 in fiscal Q4 and 657 for the full year [3] Visit Volumes - Visit volumes for fiscal Q4 increased by 18% to 2.4 million, while full year visit volumes rose by 14% to 9.0 million [4] Future Guidance - For the full year 2026, LifeStance anticipates revenue between $1.615 billion and $1.655 billion, center margin of $526 million to $550 million, and adjusted EBITDA of $185 million to $205 million [4] Company Overview - LifeStance Health Group provides outpatient mental health services, including psychological testing, psychiatric evaluations, and various therapy options, operating through a mental health platform with both virtual and in-person care [5]

Market Trends - The market is currently experiencing a focus on AI outcomes, particularly in capital expenditures related to hyperscalers and disruptive model frameworks [2] - There is a perception that the market is acting indiscriminately, with a "shoot first and ask questions later" mentality, leading to potential disruptions as models are developed and utilized [3] - Despite the S&P being flat over the last four months, there has been aggressive cyclical rotation, indicating significant disruptions ahead that are prompting investors to recalibrate their portfolios [4] Economic Outlook - The economic backdrop remains relatively healthy, supported by monetary and fiscal policies, with expectations of two interest rate cuts by the Fed likely through the summer [4] - Tax rebates are anticipated to support consumer spending, although a bifurcated consumer landscape may emerge, reflecting a K-shaped economic recovery [4] Stock Recommendations - A list of 10 hot stocks under $20 has been compiled, focusing on those that have gained at least 20% over the past six months and are favored by analysts [7] - The methodology for selecting these stocks involved analyzing hedge fund sentiment, with the aim of outperforming the market by following top stock picks from elite hedge funds [8] Company Highlights - **LifeStance Health Group, Inc. (NASDAQ:LFST)**: - Price target raised to $10 from $9 by Canaccord, with expectations of strong growth in fiscal Q4 results and 2026 guidance, projecting revenue and adjusted EBITDA increases of 15% and 24% respectively [9][10] - Reported fiscal Q4 revenues of $382.2 million, a 17% increase year-over-year, and full-year revenue of $1.424 billion, up 14% [10] - Anticipates 2026 revenue between $1.615 billion and $1.655 billion, with adjusted EBITDA expected to be between $185 million and $205 million [11] - **Ondas Inc. (NASDAQ:ONDS)**: - Maintained a Buy rating with a price target of $16 by Northland Securities, highlighting successful deployment of C-UAS solutions to a German State Police office [13][14] - The company is entering a multi-billion-dollar segment in the counter-UAS market with the launch of Sentrycs Scout [14] - Received a reaffirmed Buy rating from Lake Street with a price target of $19, focusing on its wireless radio systems for secure business-to-business networks [15]

Financial Restrictions and Governance - The 2024 Credit Agreement imposes significant operating and financial restrictions, including a maximum leverage ratio compliance requirement at the end of each fiscal quarter [232]. - The company is classified as a "controlled company," qualifying for exemptions from certain corporate governance requirements, which may limit stockholder protections [238]. - The company’s governance documents may complicate acquisition attempts and management changes, affecting stockholder opportunities [248]. - The exclusive forum provisions in the company’s certificate of incorporation may limit stockholders' ability to choose favorable judicial forums for disputes [249]. Internal Control and Reporting - The company has identified material weaknesses in internal control over financial reporting, which could impair the accuracy of financial statements and investor confidence [241]. - The company has made progress in remediating identified material weaknesses but must maintain effective internal controls to avoid misstatements in financial reporting [245]. - The company’s internal control deficiencies could lead to misstatements impacting financial statements, necessitating ongoing revisions to governance practices [244]. Financial Performance and Costs - The company may incur increased costs due to compliance with public company responsibilities, including legal and accounting expenses [240]. - The company does not expect to pay any dividends for the foreseeable future, with future dividend declarations at the discretion of the Board of Directors [257]. - As of December 31, 2025, the company had an aggregate principal amount of $282.8 million outstanding under its credit facilities [369]. - The company believes that an increase or decrease in interest rates of 100 basis points would not have a material effect on its business or financial condition [369]. - Inflation has not had a material effect on the company's operating results, but future inflation could adversely impact financial condition [370]. Market Risks and Stock Performance - Market risk exposure is primarily due to potential changes in inflation or interest rates, with interest rate risk being highly sensitive to various economic factors [368]. - The stock price is highly volatile and may fluctuate significantly due to various factors, including market conditions and operating performance [255]. - The trading market for the company's shares is influenced by analysts' reports, and unfavorable research could lead to a decline in stock price [258]. Conflicts of Interest - Principal Stockholders control approximately 53.7% of the common stock, allowing them to influence corporate decisions and potentially affect stockholder interests [234]. - Potential conflicts of interest may arise from Principal Stockholders who may invest in competing businesses, which could affect the company's prospects [253]. - The company renounces any interest in corporate opportunities that may arise, which could adversely impact its business [252]. Debt and Growth Limitations - The restrictive covenants may limit the company's ability to incur additional debt, make investments, or alter business operations, potentially hindering growth strategies [235].

Financial Data and Key Metrics Changes - LifeStance Health achieved a revenue growth of 17% year-over-year in Q4 2025, reaching $382 million, and a full-year revenue of $1.424 billion, up 14% year-over-year [16][22] - Adjusted EBITDA for Q4 was $49 million, a 49% increase year-over-year, with a margin of 12.8%, the highest in the company's history as a public entity [18][22] - The company reported a positive net income and earnings per share for the full year, achieving this milestone one year ahead of expectations [19] Business Line Data and Key Metrics Changes - The clinician base grew by 9% year-over-year, totaling 8,040 clinicians, with net clinician additions of 657 for the full year [17] - Visit volumes increased by 18% year-over-year in Q4, totaling 2.4 million visits, driven by improved clinician productivity [16][17] Market Data and Key Metrics Changes - LifeStance Health's patient Net Promoter Score was 84, indicating high patient satisfaction, and the centers maintained an average Google rating of 4.7 stars [6][7] Company Strategy and Development Direction - The company plans to continue expanding its operational and clinical excellence by focusing on technology investments, including a transition to a new EHR system expected to improve clinician and patient experiences [11][73] - LifeStance aims to attract new patients through enhanced referral programs and improved patient engagement strategies, including a new care matching algorithm [12][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue growth of approximately 15% in 2026, driven by low double-digit visit growth and modest increases in total revenue per visit [30] - The company anticipates continued demand for high-quality mental health services as patients shift from cash pay to insurance for affordability [14] Other Important Information - LifeStance announced a share repurchase program of up to $100 million, funded by cash on hand, to enhance long-term shareholder value [21] - The company expects to open 20 to 30 new centers in 2026, which will initially have lower margins but are expected to contribute positively to growth [24][83] Q&A Session Summary Question: Impact of productivity initiatives on business - Management noted that productivity improvements from scheduling and clinician incentives have shown durability and are expected to continue benefiting the business into 2026 [29] Question: ROI on technology investments - The management emphasized a disciplined approach to evaluating the return on investments in technology, ensuring they align with operational goals [31] Question: Visits per clinician increase - Management explained that increased clinician availability and improved patient conversion rates through AI tools contributed to the rise in visits per clinician [34][35] Question: Payer relationships and rate increases - Management confirmed that they have largely completed cleaning up payer contracts, resulting in improved administrative efficiency and constructive conversations with payers regarding rate increases [38] Question: New center openings and margin expectations - Management acknowledged that new centers typically start with lower margins but are fully accounted for in the guidance provided [82][83] Question: Competitive landscape observations - Management indicated that the competitive environment remains strong for attracting and retaining clinicians, with no significant changes noted in the broader competitive landscape [85]

Lifestance Health Group (NasdaqGS:LFST) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Company ParticipantsDave Bourdon - CEOJack Slevin - VP of Healthcare Services Equity ResearchKen Burdick - Executive ChairmanLisa Gill - Managing DirectorMatthew Mardula - Equity Research AssociateMonica Prokocki - VP of Finance and Investor RelationsRichard Close - Managing DirectorRyan McGroarty - CFOConference Call ParticipantsCraig Hettenbach - Managing Director and Equity AnalystDavid Larsen - Managing Director ...

Financial Data and Key Metrics Changes - In Q4 2025, revenue grew 17% year-over-year to $382 million, driven by better-than-expected total revenue per visit and visit volumes [15] - Full year revenue reached $1.424 billion, up 14% year-over-year, entirely driven by visit volumes [16] - Adjusted EBITDA for Q4 was $49 million, a 49% year-over-year increase, with margins at 12.8%, the highest in the company's history as a public entity [17] - Full year Adjusted EBITDA was $158 million, increasing 32% year-over-year, with margins expanding by 150 basis points to 11.1% [17] - Free cash flow for Q4 was $47 million, totaling $110 million for the full year, exceeding expectations [18] Business Line Data and Key Metrics Changes - The company achieved a 9% growth in clinician base, totaling 8,040 clinicians, with 657 net additions for the full year [16] - Visit volumes increased by 18% year-over-year to 2.4 million in Q4, with visits per average clinician up 7% year-over-year [15][16] - Total revenue per visit was approximately flat year-over-year at $160, slightly ahead of expectations [16] Market Data and Key Metrics Changes - The company reported a patient Net Promoter Score of 84, indicating high patient satisfaction [4] - LifeStance maintained an average Google rating of 4.7 stars across over 570 centers, reflecting strong market presence and patient experience [4] Company Strategy and Development Direction - The company plans to continue expanding its operational and clinical excellence, focusing on technology and AI to enhance patient access and clinician productivity [10][11] - A transition to a new EHR vendor is underway, expected to improve interoperability and support clinician and patient experiences [10] - The company aims to open 20 to 30 new centers in 2026, contributing to growth despite initially lower margins [22][78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 15% revenue growth in 2026, driven by low double-digit visit growth and low to mid-single digit increases in total revenue per visit [27] - The company anticipates continued demand for high-quality mental health services, particularly as patients shift from cash pay to insurance for affordability [12] - Management highlighted the importance of maintaining constructive conversations with payers regarding reimbursement rates, aiming for low to mid-single digit increases [36][74] Other Important Information - The board authorized a share repurchase program of up to $100 million, funded by cash on hand, to enhance shareholder value [19] - The company is actively exploring M&A opportunities, focusing on smaller, strategically aligned targets for geographic expansion [43] Q&A Session Summary Question: Impact of productivity initiatives on business - Management noted that productivity improvements from scheduling and clinician incentives have shown durability into Q4 and 2026 [26] Question: Path to 15% EBITDA margin and ROI on technology investments - Management emphasized a disciplined approach to evaluating technology investments to ensure they drive operational leverage [29] Question: Visits per clinician increase and role of digital tools - Management explained that increased clinician availability and improved patient conversion rates through AI tools contributed to the rise in visits per clinician [32][33] Question: Status of payer relationships and rate negotiations - Management confirmed that they have largely completed cleaning up payer contracts, resulting in improved administrative efficiency and constructive discussions with payers [36] Question: New center openings and margin expectations - Management acknowledged that new centers typically start with lower margins but are expected to reach normal levels quickly, which is factored into guidance [78] Question: Trends in patient referrals and partnerships - Management highlighted that referrals remain a primary channel for new patients, with ongoing investments in partnerships to enhance patient acquisition [64]

Reimagining Mental Health Q4 2025 Earnings Presentation • February 25, 2026 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and first quarter guidance and ...

SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. (All results compared to prior-year comparative period, unless otherwise noted)2025 Highlights and 2026 Outlook Fourth quarter revenue of $382.2 million increased 17% and full year revenue of $1,424.3 million increased 14%Clinician base increased ...

Financial Performance - Fourth quarter revenue increased 17% to $382.2 million, and full year revenue grew 14% to $1,424.3 million compared to $1,251.0 million in the previous year[3] - Net income for the fourth quarter was $11.7 million, compared to a loss of $7.1 million in the prior year, and full year net income was $9.7 million versus a loss of $57.4 million[3] - Adjusted EBITDA for the fourth quarter was $48.8 million, a 49% increase, and for the full year, it grew 32% to $157.7 million[3] - Total revenue for 2025 reached $1,424,285, an increase of 13.8% from $1,250,970 in 2024[19] - Net income for 2025 was $9,663, compared to a net loss of $57,443 in 2024, marking a significant turnaround[19] - Adjusted EBITDA increased to $157,671,000 in 2025, up from $119,742,000 in 2024 and $59,042,000 in 2023, reflecting a strong operational performance[24] Operational Metrics - The clinician base expanded by 9% to 8,040 clinicians, with a net increase of 44 in the fourth quarter and 657 for the full year[3] - Fourth quarter visit volumes rose 18% to 2.4 million, while full year visit volumes increased 14% to 9.0 million[3] - Center Margin for the fourth quarter was $126.3 million, representing 33.0% of total revenue, and for the full year, it was $461.1 million, or 32.4% of total revenue[9] - Center margin for 2025 was $461,099, an increase of 14.6% from $402,399 in 2024[22] Cash Flow and Assets - The company generated $57.6 million in net cash from operations in the fourth quarter and $146.2 million for the full year[4] - Cash and cash equivalents increased to $248,642 in 2025, up 60.8% from $154,571 in 2024[21] - Total assets grew to $2,203,933 in 2025, compared to $2,118,298 in 2024, reflecting a 4.0% increase[17] - Net cash provided by operating activities was $146,151 in 2025, a significant improvement from $107,260 in 2024[21] Debt and Liabilities - Long-term debt decreased to $265,927 in 2025 from $279,790 in 2024, a reduction of 4.9%[17] - Total current liabilities rose to $251,962 in 2025, compared to $228,886 in 2024, indicating a 10.1% increase[17] Shareholder Returns and Future Projections - The Board of Directors approved a $100 million share repurchase program to return capital to shareholders while maintaining a healthy balance sheet[2] - LifeStance expects full year 2026 revenue to be between $1.615 billion and $1.655 billion, with Adjusted EBITDA projected between $185 million and $205 million[10] - The company anticipates first quarter 2026 revenue to be between $380 million and $400 million, with Center Margin expected to be between $118 million and $132 million[10] Cost Management and Investments - Operating expenses totaled $1,400,137 in 2025, up from $1,282,583 in 2024, primarily driven by center costs and general administrative expenses[19] - Interest expense decreased to $11,662,000 in 2025 from $26,535,000 in 2024, indicating improved financial management[24] - Stock-based compensation expense was $74,701,000 in 2025, slightly down from $76,172,000 in 2024, showing a focus on cost control[24] - Litigation costs for 2025 were $1,153,000, a decrease from $1,591,000 in 2024, suggesting a reduction in legal challenges[24] - The company incurred $1,626,000 in amortization of cloud-based software implementation costs in 2025, reflecting ongoing investments in technology[24] - Real estate optimization and restructuring charges were $(134,000) in 2025, indicating a positive shift in asset management compared to $(309,000) in 2024[24] - The company is undergoing a multi-phase system upgrade as part of strategic initiatives, which includes significant investments in enterprise-wide systems[24] - The company continues to evaluate and adopt critical systems for human resources management and clinician credentialing, indicating a focus on operational efficiency[24]

Core Viewpoint - LifeStance Health Group, Inc. is set to release its fourth quarter and full year 2025 earnings on February 25, 2026, before market opening [1] Group 1: Earnings Release Information - The earnings release will occur before the market opens on February 25, 2026 [1] - A live earnings conference call will be held on the same day at 8:30 a.m. Eastern Time [2] - Participants can join the call by dialing specific domestic and international numbers and using a conference ID [2] Group 2: Webcast and Replay - A real-time audio webcast will be available on the LifeStance Investor Relations website, with related materials posted prior to the call [3] - A replay of the webcast will be accessible after the conference call concludes [3] Group 3: Company Overview - LifeStance Health, founded in 2017, is one of the largest providers of outpatient mental health care in the U.S. [4] - The company offers both virtual and in-person services for various mental health conditions, catering to children, adolescents, and adults [4] - LifeStance employs approximately 8,000 mental health professionals and operates over 550 centers across 33 states [4]